RTTNews·2026-02-03 16:38Core Viewpoint - aTyr Pharma has received FDA acceptance for a Type C meeting to discuss the Phase 3 EFZO-FIT study results for efzofitimod in pulmonary sarcoidosis [1][2] Group 1: Meeting Details - The Type C meeting is scheduled for mid-April 2026 and will focus on reviewing clinical data and determining next steps for the efzofitimod program [1][2] - aTyr plans to provide an update after receiving the official meeting minutes [2] Group 2: Study Results - The EFZO-FIT study did not meet its primary endpoint; however, a clinical benefit was observed at the 5.0 mg/kg dose across multiple secondary measures [2] - Improvements were noted in patient-reported outcomes and maintenance of lung function, with a safety profile consistent with prior studies [3] Group 3: Market Reaction - aTyr's stock closed at $0.92, reflecting an increase of $0.05 or 5.17 percent on the Nasdaq [3]